Skip to content

A randomized, open label, placebo-controlled trial for platelet-rich plasma(PRP) combined with topical 5% minoxidil in the treatment of male androgenic alopecia

A randomized, open label, placebo -controlled trial for platelet-rich plasma (PRP) combined with topical 5% minoxidil in the treatment of male androgenic alopecia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034976
Enrollment
Unknown
Registered
2020-07-26
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenic alopecia

Interventions

Experimental group:5% minoxidil solution, 1ml for external application each time,twice a day for 6 months. On this basis, it is combined with local injection of PRP, 0.15 ml/cm2 each time, monthly, 3
Control group:5% minoxidil solution, 1ml for external application each time, twice a day for 6 months. On this basis, it is combined with local injection of 0.9% normal saline, 0.15 ml/cm2 each time,

Sponsors

Shanghai Tongji Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. The typical clinical manifestations were consistent with the diagnosis of AGA, and the degree of alopecia accorded with the BASP classification of androgenic alopecia; 2. Patients with good general condition (no previous heart, systemic, scalp diseases) did not use any drugs that may affect hair growth (antihypertensive drugs, hormones, cytotoxic drugs, drugs with anti androgen effect, etc.) within 3 months before the study; 3. Patients who agree to participate in observation and follow-up, are willing to accept follow-up and can cooperate closely in the whole process.

Exclusion criteria

Exclusion criteria: 1. Patients who took finasteride orally within 18 months before the start of the trial; 2. Patients who use local or systemic drugs that affect hair growth within 12 months; 3. Patients with history of hair transplantation; 4. The patient's scalp may be affected by the growth of the scalp or the whole body.

Design outcomes

Secondary

MeasureTime frame
Severity of Alopecia Tool, SALT;Evaluation of hair regeneration rate;The hair thickness and hair density of AGA patients before and after treatment are measured by Dermatoscope, and the improvement is judged by comparing the median hair density and width .;Evaluation of subjective satisfaction of patients;The quality of life (Qol) of patients is investigated by using the international dermatological quality of life questionnaire;

Primary

MeasureTime frame
The same photographic method, according to 7-point rating scale by P. Suchonwanit.;

Countries

China

Contacts

Public ContactHuang Xin

Shanghai Tongji Hospital

alida_huang@163.com+86 13524601485

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026